Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$3.15 - $7.94 $198,972 - $501,538
-63,166 Reduced 70.62%
26,282 $83,000
Q4 2021

Feb 11, 2022

BUY
$7.8 - $14.38 $49,764 - $91,744
6,380 Added 7.68%
89,448 $1.27 Million
Q3 2021

Nov 12, 2021

SELL
$7.76 - $29.37 $737,200 - $2.79 Million
-95,000 Reduced 53.35%
83,068 $665,000
Q2 2021

Aug 13, 2021

BUY
$24.17 - $34.28 $470,348 - $667,088
19,460 Added 12.27%
178,068 $5.09 Million
Q1 2021

May 12, 2021

BUY
$11.61 - $32.08 $1.28 Million - $3.54 Million
110,442 Added 229.29%
158,608 $4.61 Million
Q4 2020

Feb 12, 2021

BUY
$5.47 - $12.1 $101,572 - $224,684
18,569 Added 62.74%
48,166 $575,000
Q3 2020

Nov 12, 2020

BUY
$6.0 - $7.79 $177,582 - $230,560
29,597 New
29,597 $204,000

Others Institutions Holding EPIX

About ESSA Pharma Inc.


  • Ticker EPIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,073,100
  • Market Cap $72.3M
  • Description
  • ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...
More about EPIX
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.